Avatrombopag
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
- Avatrombopag
- Pharmacist Assessment Report
- Avatrombopag: Thrombopoietin receptor agonist → marcothrombocytopenia with mitral valve insufficiency
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Canada Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Avatrombopag: Thrombopoietin receptor agonist → marcothrombocytopenia with mitral valve insufficiency
One-Sentence Summary
Avatrombopag is an oral thrombopoietin receptor (TPO-R) agonist that stimulates platelet production. The TxGNN model predicts it may be useful for marcothrombocytopenia with mitral valve insufficiency, but no clinical trials and no publications were found in the data compiled for this report, so the prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | marcothrombocytopenia with mitral valve insufficiency |
| TxGNN Prediction Score | 0.9999 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 1 of 1) |
| Number of DINs | 1 (marketed: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Avatrombopag belongs to the class of oral TPO-R (c-Mpl) agonists, which stimulate megakaryocyte proliferation and thereby increase platelet production.
A hereditary macrothrombocytopenia with low platelet counts could plausibly respond if the underlying defect lies in thrombopoiesis rather than in platelet destruction or a structural defect of the megakaryocyte. The mitral valve component would not be expected to respond to this drug.
The underlying genetic cause of the predicted condition is unspecified, so the mechanistic link is speculative. The score is a model-based prediction only.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02542706 | DOPTELET | Not recorded | Not recorded |
Safety Considerations
- Drug Interactions: 52 interactions were found in the interaction database. Examples of those rated Major: fosphenytoin, carbamazepine, carfilzomib, dabrafenib, enzalutamide, fluconazole and imatinib. Examples rated Moderate: clarithromycin, nitisinone, cobicistat, fosamprenavir, gemfibrozil, fenofibrate, apalutamide, atazanavir, amprenavir, boceprevir, ceritinib, delavirdine and idelalisib.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by the model score, with no clinical trials or publications, an unspecified genetic cause, and a component (mitral valve insufficiency) that is not expected to respond to the drug. The evidence level is L5.
To proceed, the following is needed:
- Clinical or literature evidence of avatrombopag in this specific condition or closely related inherited macrothrombocytopenias
- Definition of the underlying genetic cause and whether the defect lies in thrombopoiesis
- Package insert warnings and contraindications from Health Canada
- Detailed mechanism of action data
- A review of the interactions rated Major and a safety plan for patients on those drugs
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.